NeurAxis Positions for Next Phase of Commercial Growth with Appointment of Craig Blanchard as Chief Commercial Officer

The hire adds commercial leadership as NeurAxis prepares to expand its sales organization and anticipates more covered lives.

Rhea-AI Summary

NeurAxis (NRXS) appointed Craig Blanchard chief commercial officer to oversee its sales and marketing functions. The company expects to expand its commercial organization and anticipates a substantial increase in covered lives as it seeks broader adoption of IB-Stim. Blanchard previously held commercial leadership roles at NICO, Boston Scientific and Guidant.

2 points · 0 major

PositiveiHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 0 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Moderate point. Forward-looking: it has not happened yet and may not happen.NeurAxis anticipates a substantial increase in covered lives.
• Minor point. Forward-looking: it has not happened yet and may not happen.NeurAxis expects to expand its commercial organization to support IB-Stim adoption.

Negative

• None.

Market Context

The September 16 policy added access for 18 million members, connecting this appointment to an earli...

Analysis

The September 16 policy added access for 18 million members, connecting this appointment to an earlier expansion of coverage relevant to the company's stated commercial growth plans.

Historical Context

1 past event · Latest: Sep 16

1 event

1. Sep 16

   payer coverage expansion

   24h Move

   +22.3%

   New insurer policy expanded PENFS access by approximately 18 million covered lives.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

neuromodulation, ibs, off-label, fda-cleared

4 terms

neuromodulation medical

"a medical technology company commercializing neuromodulation therapies"

Neuromodulation is the use of devices or targeted treatments to change how nerves or brain circuits send signals, much like adjusting the volume or tuning on an audio system to alter what you hear. For investors, it matters because these therapies can treat chronic conditions (pain, movement disorders, depression) where existing medicines fall short, creating potential markets, regulatory milestones, and durable revenue streams if technologies prove safe and effective.

ibs medical

"irritable bowel syndrome (IBS)"

Irritable bowel syndrome (IBS) is a common chronic digestive disorder that causes stomach pain, bloating and changes in bowel habits (diarrhea, constipation, or both) without visible structural damage. It matters to investors because large numbers of patients, limited effective treatments and the potential for new drugs or therapies mean clinical trial results, regulatory approvals and product launches can significantly affect a healthcare company's revenue and valuation—think of it as a widespread household problem that a new, effective product could solve.

off-label medical

"off-label prescription drugs are often used"

Off-label describes the use of an approved drug or medical device for a purpose, patient group, dose, or method that is not listed on its official regulatory label. Think of it like using a tool for a different job than the manufacturer describes: it can expand real-world demand but also raises questions about safety, reimbursement, and legal risk. Investors watch off-label use because it can boost sales quickly but may increase regulatory scrutiny, liability, or unpredictable revenue sustainability.

fda-cleared regulatory

"IB-Stim, is FDA-cleared for the treatment"

FDA-cleared means a medical product—typically a device or diagnostic—has passed a U.S. regulator’s review showing it is substantially similar to an existing approved product and is safe and effective for its intended use. For investors, clearance acts like an official safety stamp that lowers regulatory risk and can speed market access, comparable to getting a trusted roadworthy certificate before selling cars, which can make sales and adoption happen faster.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CARMEL, Ind., Sept. 29, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced the appointment of Craig Blanchard as Chief Commercial Officer. In this role, Mr. Blanchard will oversee the Company’s commercial functions, including sales and marketing.

The appointment of Mr. Blanchard as Chief Commercial Officer represents a strategic investment in the significant growth opportunity NeurAxis sees ahead. With the Company expecting to expand its commercial organization alongside a substantial increase in covered lives, NeurAxis is strengthening its leadership and sales infrastructure to support broader adoption of IB-Stim and capitalize on its expanding market opportunity.

“Craig joins NeurAxis at an important inflection point in our commercial growth,” said Brian Carrico, President and Chief Executive Officer of NeurAxis. “As we prepare to significantly expand our commercial organization and anticipate a substantial increase in covered lives, his experience building sales teams, launching innovative medical technologies and driving market adoption will be invaluable. We believe Craig’s leadership will help us translate expanding reimbursement coverage into broader physician adoption and increased patient access to IB-Stim.”

Mr. Blanchard brings NeurAxis extensive experience in commercialization, market development, and healthcare technology adoption. Previously, he served as Vice President of Product Strategy, Marketing and Field Clinical at NICO Corporation, where he led commercial strategy for minimally invasive neurosurgery technologies and helped drive multiple products from launch through market adoption, with NICO technologies impacting more than 40,000 patients and leading to its acquisition by Stryker in 2024.

Earlier in his career, Mr. Blanchard held commercial leadership roles at Boston Scientific and Guidant Corporation, with responsibilities spanning sales growth, national accounts, and product commercialization.

NeurAxis’ proprietary PENFS technology, IB-Stim, is FDA-cleared for the treatment of functional abdominal pain associated with irritable bowel syndrome (IBS) and Functional Dyspepsia, and FD associated nausea symptoms, in patients 8 years and older. IB-Stim is a non-invasive neuromodulation device that gently stimulates cranial nerve bundles in the ear to help regulate pain signaling between the gut and the brain. Currently, no FDA-approved drug therapies exist for pediatric patients with abdominal pain-related disorders of gut-brain interaction (DGBIs), a significant unmet medical need. In the absence of approved options, off-label prescription drugs are often used, despite limited efficacy data and potential safety concerns—underscoring IB-Stim’s unique position as the only FDA-cleared therapy specifically designed for this large and underserved pain related patient population.

About NeurAxis, Inc.
NeurAxis, Inc., is a medical technology company focused on neuromodulation therapies to address chronic and debilitating conditions in children and adults. NeurAxis is dedicated to advancing science and leveraging evidence-based medicine to drive the adoption of IB-Stim, its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, by the medical, scientific, and patient communities. IB-Stim is FDA-cleared for functional abdominal pain in irritable bowel syndrome (IBS) and functional dyspepsia, including FD-linked nausea symptoms in patients ages 8 and older. Additional clinical trials of PENFS in multiple pediatric and adult conditions with large unmet healthcare needs are underway. For more information, please visit http://neuraxis.com.

Contacts:

Company
NeurAxis, Inc.
info@neuraxis.com
For contraindications, precautions, warnings, and IFU, please see: https://ibstim.com/important-information/.

Investor Relations
Lytham Partners
Ben Shamsian
646-829-9701
shamsian@lythampartners.com